Danaher reported Q3 2026 earnings per share of $2.11, surpassing analyst estimates of $1.92, although revenue slightly missed expectations at $6.55 billion versus $6.56 billion forecast. The company highlighted improving customer demand and faster core revenue growth excluding respiratory revenue, attributing double-digit adjusted EPS growth to stronger demand and operational improvements via the Danaher Business System. Key financial ratios include a trailing P/E of 36.6 and a debt-to-equity ratio of 0.49, indicating solid financial health. These results suggest Danaher's continued strength in life sciences and diagnostics amid competitive pressures.
Danaher shares are trading at USD 230.05 on Pluang as of Oct 21, 2026 21:32 WIB, showing a 1-day gain of 2.70%. The stock's market cap stands at $157.64 billion, reflecting its significant presence in the health sector. Despite the strong earnings report, Pluang order activity leans heavily towards selling, with 79% of orders being sell orders at this time.
